Sofosbuvir/velpatasvir is one of the most important hepatitis C treatments ever made: a single daily tablet that cures nearly everyone, across every genotype, in twelve weeks. It is the medicine inside brand-name Epclusa and its authorized generic.
This is SunnyPharma’s independent, physician-reviewed guide to how well sofosbuvir/velpatasvir works, what it should cost you in the U.S., why the same drug sells for a fraction of the price elsewhere in the world under Gilead’s licensing program, and how cost-burdened patients can reach it at low or no cost.
- It cures hepatitis C. About 98–99% of patients are cured after 12 weeks in clinical trials — one pill a day.
- It works for every genotype. Sofosbuvir/velpatasvir is pan-genotypic, treating all six HCV genotypes, including the historically stubborn genotype 3.
- It is the generic in Epclusa. An FDA-approved authorized generic has been sold in the U.S. since 2019.
- Price is not the barrier it seems. The U.S. cash price is high, but Gilead Support Path and Medicaid put the cost at $0 for many who qualify.
What Sofosbuvir/Velpatasvir Is
Sofosbuvir/velpatasvir is a fixed-dose combination of two direct-acting antiviral drugs in one tablet. Sofosbuvir is an NS5B polymerase inhibitor — it blocks an enzyme the hepatitis C virus needs to copy its genetic material. Velpatasvir is an NS5A inhibitor — it disables a protein the virus uses to replicate and assemble. Used together, once a day, they stop the virus at two points at once.
The combination is sold as the brand Epclusa and, since 2019, as an FDA-approved authorized generic from Asegua Therapeutics, a Gilead subsidiary. It is taken as one tablet daily, with or without food, usually for 12 weeks. Because missing doses lets the virus rebound, taking it consistently is part of what makes the cure reliable.
How Well It Works: Cure Rates by Genotype
Hepatitis C is measured not by “improvement” but by cure — a sustained virologic response 12 weeks after treatment ends (SVR12), meaning the virus stays undetectable. By that standard, sofosbuvir/velpatasvir is one of the most effective treatments in modern medicine.
In the pivotal ASTRAL-1 trial, 12 weeks of treatment cured 99% of patients with genotypes 1, 2, 4, 5, and 6. Cure rates held up in the groups that used to be hardest to treat: about 99% in people with compensated cirrhosis, and about 99% in those whose prior treatment had failed. In HIV/HCV co-infection (the ASTRAL-5 study), the cure rate was about 95% — on par with results in people who do not have HIV.
| Group | Approx. Cure Rate (SVR12) | Notes |
|---|---|---|
| Genotypes 1, 2, 4, 5, 6 (ASTRAL-1) | ~99% | 12-week treatment, single tablet daily |
| Compensated cirrhosis | ~99% | High cure rate maintained |
| Prior treatment failure | ~99% | Effective after earlier regimens failed |
| HIV/HCV co-infection (ASTRAL-5) | ~95% | On par with HIV-negative patients |
| Genotype 3 with cirrhosis | Lower | May warrant added ribavirin or extended therapy |
Cure rates from the ASTRAL trial program (Feld JJ et al., NEJM 2015; ASTRAL-4 and ASTRAL-5).
Why “Pan-Genotypic” Matters
Hepatitis C comes in six main genotypes, and older treatments only worked on some of them — so patients needed genotype-specific regimens, and genotype 3 in particular was notoriously difficult. Sofosbuvir/velpatasvir changed that: it is pan-genotypic, effective across all six. A blood test still identifies your genotype, because for genotype 3 with cirrhosis a clinician may add ribavirin or adjust the plan. But for most people, one regimen now fits regardless of genotype — which is exactly why it became a first-line cure worldwide.
What It Costs in the U.S.
The sticker prices are steep, but they are rarely what a cost-burdened patient actually pays.
| Option | Roughly What It Costs (28 tablets) | Key Notes |
|---|---|---|
| Brand Epclusa | $24,000–$35,000 | Full cash price for a 12-week course |
| Authorized generic (sofosbuvir/velpatasvir) | $6,700–$7,800 | Cheaper than brand but still high |
| Gilead Support Path (eligible uninsured) | $0 | Free medicine for qualifying uninsured patients |
| Medicaid (most states) | $0 | Covered with little or no copay |
Prices approximate, 2026. Actual cost depends on plan design, pharmacy, and assistance eligibility.
The practical takeaway is that your coverage matters more than the price tag. Many people with Medicaid pay nothing, and Gilead’s Support Path can supply the medicine at no charge to eligible uninsured patients. The cash price only becomes the deciding number if you fall outside those programs.
See the lowest-cost path you qualify for. Our free Hepatitis C Treatment Access screener asks four quick questions and points you toward Medicaid, Gilead Support Path, or a foundation — whichever fits your situation. No sign-up.
The Same Drug, a Fraction of the Price: The Global Generic
One of the reasons sofosbuvir/velpatasvir matters so much is that it was made affordable across the developing world. When Gilead brought the drug to market, it signed voluntary licensing agreements with 11 India-based manufacturers — among them Mylan, Natco, Cipla, Hetero, Aurobindo, and Laurus — permitting them to make and sell generic sofosbuvir/velpatasvir in roughly 101 lower- and middle-income countries in exchange for a royalty to Gilead.
The effect on price was dramatic. In those licensed countries, a full 12-week generic course has been reported at around $300 — against tens of thousands of dollars in the U.S. A Pennsylvania State University cost-effectiveness analysis found that at those prices the pan-genotypic regimen was highly cost-effective for hepatitis C programs where the licensed generics are available. This is the licensing arrangement that put a hepatitis C cure within reach for millions of people who could never have afforded the brand.
Important for U.S. readers: That Gilead license is geographically restricted. It covers named lower-income countries but not the United States, and it excludes a number of middle-income countries where tens of millions of people with hepatitis C live. Because the Indian generics are licensed for other markets, they are not FDA-approved for U.S. sale, and importing an unapproved prescription drug into the U.S. is generally not permitted for personal use. The low global price is a real achievement — it is not a legal U.S. purchasing route.
Side Effects and Safety
For most people sofosbuvir/velpatasvir is well tolerated. The most common side effects are mild: headache and fatigue. A few safety points carry more weight and are worth knowing before you start.
- Hepatitis B reactivation (boxed warning). In anyone who has ever had hepatitis B, curing hepatitis C can reactivate the hepatitis B virus and cause serious liver problems, including liver failure. Everyone is screened for hepatitis B before treatment for this reason — a step that is dangerously easy to skip when medicine is bought without a prescriber.
- Amiodarone interaction. Taken with the heart-rhythm drug amiodarone, sofosbuvir-based regimens can cause a dangerously slow heart rate, occasionally requiring a pacemaker. The combination is generally avoided.
- Ribavirin adds side effects. When ribavirin is added (for example, in decompensated cirrhosis), anemia and other effects can occur, so monitoring increases.
Why a prescriber matters: The genotype test, the hepatitis B screen, and the amiodarone check all happen because a clinician is involved. They are the difference between a safe cure and a preventable harm — and the main reason buying pills alone, without a prescription, is riskier than it looks.
Sofosbuvir/Velpatasvir vs. Other Hepatitis C Drugs
Sofosbuvir/velpatasvir is not the only cure. Ledipasvir/sofosbuvir (generic Harvoni) is closely related but is genotype-restricted — mainly genotypes 1, 4, 5, and 6 — so it is not a first choice for genotypes 2 or 3. Glecaprevir/pibrentasvir (Mavyret) is another pan-genotypic option that can be as short as 8 weeks for some patients. The best regimen for you depends on your genotype, any prior treatment, and whether you have cirrhosis — which is a decision for your prescriber, not a price comparison.
Frequently Asked Questions
What is sofosbuvir/velpatasvir used for?
It is a once-daily, single-tablet treatment for chronic hepatitis C. It is pan-genotypic — it treats all six major HCV genotypes (1 through 6) — in adults and children 3 and older, with or without compensated cirrhosis. It is the generic combination sold as Epclusa, and for decompensated cirrhosis it is given with ribavirin.
How effective is sofosbuvir/velpatasvir?
Very effective. In the pivotal ASTRAL-1 trial, 12 weeks produced a cure (SVR12) in 99% of patients with genotypes 1, 2, 4, 5, and 6, with about 99% cure rates in compensated cirrhosis and after prior treatment failure. A sustained virologic response 12 weeks after treatment is considered a cure.
Does sofosbuvir/velpatasvir work for all hepatitis C genotypes?
Yes. It is pan-genotypic and effective across all six major genotypes, including genotype 3, historically the hardest to cure. For genotype 3 with cirrhosis, a clinician may add ribavirin or extend therapy, so genotype and liver status still guide the exact plan.
How much does sofosbuvir/velpatasvir cost in the US?
The authorized generic runs roughly $6,700 to $7,800 cash for 28 tablets, versus about $24,000 to $35,000 for brand Epclusa. But Gilead’s Support Path can supply it at no charge to eligible uninsured patients, and many people with Medicaid pay $0, so coverage matters more than the sticker price.
Is sofosbuvir/velpatasvir a Gilead-licensed generic outside the US?
Yes. Gilead granted voluntary licenses to 11 India-based manufacturers to produce generic sofosbuvir/velpatasvir for about 101 lower- and middle-income countries, where a 12-week course has been reported near $300. The license is geographically restricted, does not cover the U.S., and excludes some middle-income countries, so those versions are not FDA-approved for U.S. sale.
What are the side effects of sofosbuvir/velpatasvir?
The most common are mild — headache and fatigue. The key safety point is a boxed warning for hepatitis B reactivation, so everyone is screened for hepatitis B before starting. Taking it with the heart-rhythm drug amiodarone can cause a dangerously slow heart rate and is generally avoided.
How is sofosbuvir/velpatasvir taken?
One tablet by mouth once a day, with or without food, usually for 12 weeks. Missing doses can lower the drug level and reduce the chance of cure. Your prescriber confirms the duration and whether ribavirin is added based on your genotype and cirrhosis status.
Is sofosbuvir/velpatasvir the same as Epclusa?
Yes. Epclusa is the brand name; sofosbuvir/velpatasvir is the generic name for the same two ingredients at the same 400 mg/100 mg strength. Gilead’s subsidiary Asegua Therapeutics has sold an authorized generic in the U.S. since 2019, expected to work identically to the brand.
- Generic for Epclusa — what it costs and whether it saves you money
- Epclusa price in the USA — what patients pay and every $0 pathway
- Hepatitis C Treatment Access screener — find your lowest-cost route in about a minute
How we reviewed this article:
SunnyPharma follows strict sourcing guidelines and relies on peer-reviewed studies (NEJM, ASTRAL trial program), government agencies (FDA, CMS, HRSA), academic research institutions, and drug-manufacturer prescribing information and licensing disclosures. We use only credible, verifiable sources to ensure accuracy.
Read our editorial policy →Sources & References
- Feld JJ, Jacobson IM, Hézode C, et al. — Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection (ASTRAL-1), NEJM 2015: nejm.org
- ASTRAL trial program (ASTRAL-1 through ASTRAL-5); SVR12 across genotypes, cirrhosis, and HIV/HCV co-infection.
- FDA / Gilead — EPCLUSA Prescribing Information (boxed warning: hepatitis B reactivation; amiodarone interaction; dosing): gilead.com
- Gilead Sciences — Chronic Hepatitis C Generic Licensing Agreement Fast Facts (11 India-based manufacturers): gilead.com
- Pennsylvania State University / J Gastroenterol Hepatol — Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir (2018): pubmed.ncbi.nlm.nih.gov
- Gilead Support Path — patient assistance (mysupportpath.com), 1-855-769-7284.